Bial, a biopharma company focused on innovation in neurosciences and rare diseases, has shared updates on its Phase 2 study named ACTIVATE (NCT05819359). This trial
Lindus Health, known for running clinical trials much faster and more reliably, and Frieda Health, a Berlin‑based femtech company, have announced that their clinical trial
Clinical Trial Applications underway in Russia, Brazil, and Mexico Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial
Raytone Biotech, a biotech company that focuses on creating new treatments for eye diseases, has shared that the first patient was given the treatment RTP-008
Nicox SA, an international ophthalmology company, announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX
Topline results and full data analysis expected in Q4 2025 BioStem Technologies, a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived
In an investigator-sponsored study of OM336, two patients with relapsed/refractory autoimmune hemolytic anemia showed rapid and sustained remissions out to month six, without other immunosuppressive
New case study shows 64% of participants represent diverse populations While clinical trials have historically struggled with participation among underrepresented populations, EmVenio Research breaks the
Collaboration will support trial planning for Trace Neuroscience’s upcoming Phase 1/2 clinical trial in ALS Unlearn, a leader in AI-powered solutions for clinical trials, announced
Memorial Healthcare System is one of only four healthcare centers in the nation to have participated in a clinical trial for the Pleural Dynamics ACES System,
Program supports the Medidata Patient, Data, and Study Experiences, boosting site engagement, eliminating clinical trial inefficiencies, and increasing tech compliance Medidata, a Dassault Systèmes brand and
Health Canada’s approval enables 4Moving Biotech to initiate the INFLAM MOTION Phase 2a clinical trial 4Moving Biotech , a spin-off of 4P-Pharma dedicated to developing
